Galien Golden Jubilee Forum USA 2021

Oct. 28th, 2021
9AM – 10AM

Ann Graybiel, Institute Professor, Department of Brain and Cognitive Science, MIT

Dan Grossman, Managing Director and Senior Partner, Boston Consulting Group
Kelsey Martin, Director, Simons Foundation Autism Research Initiative (SFARI)
Michel Pairet, Member of the Board of Managing Directors – Innovation, Boehringer Ingelheim


Ann Graybiel
Institute Professor, Department of Brain and Cognitive Science

Ann M. Graybiel is an Institute Professor at the Massachusetts Institute of Technology, where she and her laboratory are actively investigating neural circuits that modulate mood, motivation and movement. These neural circuits are vulnerable in neurologic and neuropsychiatric conditions ranging from Parkinson’s disease to anxiety, depression and abnormally repetitive behavioral disturbances. Her group interacts extensively with clinicians as well as other basic scientists across several disciplines and is identifying molecular genetic markers of these circuits, with the goal of contributing to clinical medicine. On the basis of her work, Graybiel was elected to the National Academy of Sciences of the USA (1988), to the American Academy of Arts and Sciences (1991), and to the Institute of Medicine of the USA (1994). She was awarded the Dow Award in 2002, the Prix Plasticité Neuronale IBSEN in 2005, and the Vanderbilt Prize in 2008. In 2001, Graybiel was awarded the National Medal of Science of the United States, the nation’s highest science award. In 2012, Graybiel received the prestigious Kavli Prize in Neuroscience, bestowed by the King of Norway.

Dan Grossman
Managing Director and Senior Partner
Boston Consulting Group

Dan Grossman joined the Chicago office of the Boston Consulting Group in 2003, and serves as an advisor to numerous biopharma, med tech, patient advocacy, and other non-profit health care organizations. His focus is on innovation & growth strategy and environment-shaping for new-to-world therapies and diagnostics. Dan has worked extensively on innovative opportunities in the neuroscience space, spanning neurodegenerative disease such as Alzheimer’s and Parkinson’s, neurovascular interventional procedures, pain therapies, migraine treatments, and psychiatric treatments in the emerging field of psychedelic medicine. Within BCG, Dan is responsible for Health Care Practice Areas portfolio of proprietary data and tools that support a broad range of client engagements. Dan holds a PhD in mathematics from Princeton University, and prior to joining BCG, was on the faculty of the mathematics department of the University of Chicago.

Kelsey Martin
Simons Foundation Autism Research Initiative (SFARI)

Michel Pairet
Member of the Board of Managing Directors – Innovation
Boehringer Ingelheim

He is in charge of Research, non-clinical Development, Patents, Business Development and Licensing, Translational Medicine and Clinical Pharmacology, and the Corporate Venture Fund and, as such, is responsible for Boehringer Ingelheim´s internal and external strategic product sourcing.

During his career, Michel has held several positions in Research and Development. With his team, he has been involved in the discovery and development of several important medicines that address diseases with a high medical need. These include:
Nintedanib/ Ofev® (first-in-class fibrokinase inhibitor for the treatment of Idiopathic Pulmonary Fibrosis (IPF; FDA Breakthrough designation) and several other Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)).
Dabigatran/ Pradaxa® (first-in-class novel oral anticoagulant for Stroke Prevention in Atrial Fibrillation: SPAF), and idarucizumab/ Praxbind® (first specific reversal agent available for a novel oral anticoagulant).
Empagliflozin/ Jardiance® (First anti-diabetic drug to demonstrate cardiovascular risk reduction in a dedicated cardiovascular outcome study)

All of these compounds were discovered in-house at Boehringer Ingelheim. In parallel, under Michel´s leadership, a specific focus was to access external innovation. This is illustrated by important partnerships with Academic teams and Biotech companies. These collaborations have generated development compounds, which today significantly contribute to Boehringer Ingelheim’s development pipeline, characterized by a high share of projects with first in class and breakthrough potential, in the areas of oncology, cardio-metabolic diseases, inflammatory and respiratory diseases, psychiatric diseases, and retinopathies.

Michel´s R&D strategy is based on three pillars: “1) Core Therapeutic Areas, to build on our strengths, by focusing on disease areas for which we have built a strong expertise over time. 2) Scientific Platforms, to build on synergies based on scientific mechanisms and technology platforms with potential in multiple disease areas, e.g. immune modulation, fibrosis, regenerative medicine, and 3) Research Beyond Borders, little smart bets in external innovation to explore emerging science beyond our current therapeutic area focus, and prepare a timely and efficient entry into new medical and scientific fields”.

Michel holds a Doctorate in Veterinary Medicine, a PhD and a Professorship in Physiology and Pharmacology, from the University of Toulouse, France. He has been issued several patents and has published several key scientific publications and book chapters.

Jay Stamatis
Vice President, Head of Business Development and Acquisitions

Jay Stamatis joined AbbVie in December 2016 with a diverse biotech and pharma experience base spanning more than 20 years. Jay and the business development & acquisitions team he leads have executed a large variety of transactions, ranging from the acquisition of Allergan in 2019 to a multitude of product development, collaboration, option or technology platform deals across AbbVie’s key therapeutic areas.

Prior to joining AbbVie, he was the Vice President of Business Development at Atara Bio, a publicly-traded oncology and cell therapy company in the San Francisco Bay Area.  Preceding his tenure at Atara Bio, Jay worked at Acerta Pharma, another Bay Area oncology start-up, now a subsidiary of AstraZeneca, and Onyx Pharmaceuticals, until its acquisition by Amgen.  Jay also spent a number of years at Amgen and Eli Lilly in a variety of business development and commercial leadership roles.

Jay earned his Bachelor Degree in History from Tulane University and a Master of Business Administration Degree from Washington University in St. Louis.